Novo Nordisk bid raises overpayment and regulatory concerns

about 1 month ago

Chloe Malay

"But now the reason why Nova shares were down this morning is because there are concerns now arising among investors that the higher the bids go the more likely the biders will be overpaying and there's also the threat of regulatory hurdles. This antitrust concerns coming into view as well. So we'll see how this goes going forward."

Novo Nordisk's escalating bid for an obesity startup has sparked investor concerns over potential overpayment and looming antitrust issues, contributing to a decline in the shares.

Related Stocks